Posts

Windward Bio files for Nasdaq IPO to fund clinical programs

on
Windward Bio Group AG, a Basel-based clinical-stage biotech, filed an F-1 registration statement on October 23, 2026, proposing to list on the Nasdaq Global Market under ticker WWB. The company says it would use IPO proceeds to advance its antibody programs for severe asthma, COPD and atopic dermatitis, progress earlier-stage bispecific programs and support general corporate needs. The filing did not disclose a share count or price range; the reported $100 million figure is a proposed deal size, not finalized terms. Its lead candidate, WIN378, is a long-acting anti-TSLP antibody licensed from Sichuan Kelun-Biotech and Harbour BioMed. It is being tested in a Phase 2/3 severe-asthma study and a Phase 2 COPD study. WIN027, licensed from Qyuns Therapeutics, is an early-stage bispecific antibody targeting TSLP and IL-13. Windward is also emphasizing internal discovery and R&D as it builds beyond its China-originated licensed assets. Windward was founded in 2024 and launched in J...

Novartis warns MFN could reshape European drug launches

on

ESMO: Imfinzi–Padcev shows promise with less Padcev after surgery

on

J&J’s oral RIPTAC shows early activity in advanced prostate cancer

on

Lycia Therapeutics closes upsized $365.1 million IPO

on

BMS reports death in MS CAR-T trial and aims to restart studies

on

Merck–Kelun ADC shows substantial progression-free survival benefit in PD-L1-negative NSCLC

on

Imdelltra–Imfinzi combination shows major survival benefit in Phase 3 lung cancer trial

on

Analysts warm to Merck–Moderna cancer vaccine after ESMO presentation

on

Pathos raises $237M and partners with BMS and Tempus on neuroscience AI

on

BMS reports a death in an MS CAR-T trial as it reviews inflammation signals

on

Amgen combination extends survival in small cell lung cancer trial

on

Innovent reports early Phase 2 results for IBI354 in first-line HER2-positive breast cancer

on